Rinvoq Replacement in Breast Cancer Patients
Rinvoq (upadacitinib), a JAK inhibitor, should be discontinued in patients with a history of breast cancer due to increased malignancy risk, and alternative immunomodulatory therapies without the same cancer risk profile should be considered instead. 1
Why JAK Inhibitors Are Contraindicated
- JAK inhibitors carry an increased risk of malignancy recurrence in patients with prior cancer history, making them unsuitable for breast cancer patients requiring immunomodulatory therapy 1
- For patients with hormone receptor-positive breast cancer, there are additional theoretical concerns that immune modulation may impair cancer surveillance mechanisms that prevent recurrence 1
Alternative Immunomodulatory Approaches
The European Society for Medical Oncology specifically recommends considering alternative immunomodulatory therapies that do not carry the same malignancy risk profile as JAK inhibitors for patients with breast cancer history requiring treatment for inflammatory conditions 1
Specific alternatives depend on the underlying inflammatory condition requiring treatment:
- For rheumatoid arthritis or other inflammatory arthropathies: Consider conventional DMARDs (methotrexate, hydroxychloroquine, sulfasalazine) or biologic agents (TNF inhibitors, IL-6 inhibitors, abatacept) that have not demonstrated the same cancer risk signal 1
- For inflammatory bowel disease: Consider anti-TNF biologics, vedolizumab, or conventional immunosuppressants rather than JAK inhibitors 1
- For dermatologic conditions: Consider topical therapies, phototherapy, or alternative systemic agents depending on the specific condition 1
Mandatory Clinical Safeguards
If the inflammatory disease is severe and refractory to standard alternatives, consultation with both oncology and rheumatology is mandatory before considering any immunosuppressive therapy 1
Required multidisciplinary evaluation includes:
- Multidisciplinary tumor board discussion involving medical oncology, rheumatology, and the patient to weigh risks and benefits 1
- Documented informed consent specifically addressing the increased cancer risk if alternative immunosuppressive therapy is ultimately deemed necessary 1
- Baseline and serial oncologic surveillance, including mammography and clinical breast examination at shortened intervals (typically every 6 months rather than annually) 1
Breast Cancer Treatment Considerations
The choice of alternative therapy should not interfere with ongoing breast cancer treatment if the patient is still receiving active therapy:
- For patients on endocrine therapy (tamoxifen, aromatase inhibitors), ensure the alternative immunomodulatory agent does not have drug interactions or compromise cancer treatment efficacy 2, 3
- For patients receiving HER2-targeted therapy (trastuzumab, pertuzumab), coordinate timing and monitoring with the oncology team 4, 5
- For patients in surveillance after completing treatment, the recurrence risk must be carefully weighed against the severity of the inflammatory condition requiring treatment 1
Common Pitfalls to Avoid
- Never initiate or continue JAK inhibitors (including Rinvoq, tofacitinib, baricitinib) in patients with any history of breast cancer, regardless of time since diagnosis 1
- Do not make treatment decisions in isolation—always involve the patient's oncologist before starting any immunosuppressive therapy 1
- Avoid assuming that "enough time has passed" since breast cancer diagnosis—the increased malignancy risk with JAK inhibitors applies regardless of disease-free interval 1